Innovative: drug development for infertility therapy By Bernadette Maria Julia Louise Mannaerts

Innovative drug development is essential to improve therapy over time by offering better efficacy, safety and/or treatment convenience. This thesis presents the main scientific data behind the successful clinical development of three innovative fertility drugs: follitropin-β (recombinant FSH), ganirelix (GnRH antagonist) and corifollitropin alfa (recombinant long-acting FSH agonist). The development of these drugs has provided short and simple treatment options with minimal drug exposure and interventions, potentially reducing treatment-related stress and improving live birth rates for women seeking infertility treatment.